Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...

A viral 15-step handcare routine by influencer Victoria Ortega has helped fuel a growing global focus on handcare, turning hands into a new...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...

RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...

Dr Reddy's Laboratories has achieved a significant milestone. Health Canada has approved its generic semaglutide injection. This makes Dr R...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...

Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to rece...

In 2024, India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T therapy. ...

The major pharmaceutical companies of the country reported a 10 per cent year-on-year (YoY) growth in the second quarter of FY25, largely d...

47.5 mn people are affected by dementia worldwide - of which Alzheimer's is the most common form, researchers said.